NCT05860933

A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants

A Phase 1 Study to Evaluate the Effects of Multiple Doses of Itraconazole or Carbamazepine on the Single-Dose Pharmacokinetics of LY3537982 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the effect of itraconazole and carbamazepine on LY3537982 when administered as multiple doses by conducting the blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 in adult healthy participants. The study will also evaluate the safety and tolerability of LY3537982. The study is conducted in two parts. Participants will stay in the research center during the study, which will last about 11 and 15 days for part 1 and part 2, respectively, not including screening.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3537982	Administered orally.
DRUG	Itraconazole	Administered orally.
DRUG	Carbamazepine	Administered orally.

Timeline

• Start date: 2023-05-08
• Primary completion: 2023-08-28
• Completion: 2023-08-28
• First posted: 2023-05-16
• Last updated: 2024-11-08

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study